



# Corrigendum to 'Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial'

Robin von Rotz,<sup>a,\*</sup> Eva M. Schindowski,<sup>a</sup> Johannes Jungwirth,<sup>a</sup> Anna Schulte,<sup>a</sup> Nathalie M. Rieser,<sup>a</sup> Katharina Zahoransky,<sup>a</sup> Erich Seifritz,<sup>b</sup> Albina Nowak,<sup>b</sup> Peter Nowak,<sup>b</sup> Lutz Jäncke,<sup>c</sup> Katrin H. Preller,<sup>a,d</sup> and Franz X. Vollenweider<sup>a,d</sup>




<sup>a</sup>Neurophenomenology of Consciousness Lab, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zürich, Switzerland

<sup>b</sup>Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zürich, Switzerland

<sup>c</sup>Division Neuropsychology, Department of Psychology, University of Zürich, Zürich, Switzerland

We wish to provide a correction of the colour representation of Fig. 2 in order to harmonise the colours representing the Psilocybin and the Placebo condition with the corresponding figure caption and with the colour codes from all other figures across the manuscript. Fig. 2 now depicts the Psilocybin condition in blue and the Placebo condition in yellow. The error occurred as a result of an oversight. This change does not affect the results presented in the paper and the figure legend remains unchanged.

eClinicalMedicine  
2023;56: 101841  
Published Online xxx  
<https://doi.org/10.1016/j.eclim.2023.101841>



DOI of original article: <https://doi.org/10.1016/j.eclim.2022.101809>

\*Corresponding author.

E-mail address: [robin.vonrotz@bli.uzh.ch](mailto:robin.vonrotz@bli.uzh.ch) (R. von Rotz).

© 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

<sup>d</sup>Equal contribution.